Koers Teva Pharmaceutical Industries Limited Other OTC
Aandelen
TEVJF
IL0006290147
Farmaceutische producten
Omzet 2024 * | 15,86 mld. 14,8 mld. | Omzet 2025 * | 16,4 mld. 15,3 mld. | Marktkapitalisatie | 15,83 mld. 14,78 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 1,54 mld. 1,44 mld. | Nettowinst (verlies) 2025 * | 1,44 mld. 1,35 mld. | EV/omzet 2024 * | 1,93 x |
Nettoschuld 2024 * | 14,82 mld. 13,83 mld. | Nettoschuld 2025 * | 12,25 mld. 11,43 mld. | EV/omzet 2025 * | 1,71 x |
K/w-verhouding 2024 * |
11,2
x | K/w-verhouding 2025 * |
10,5
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 89,71% |
Recentste transcriptie over Teva Pharmaceutical Industries Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 01-01-23 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 22-12-19 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 01-08-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 01-09-15 |
Janet Vergis
BRD | Director/Board Member | 60 | 09-06-20 |
Sol Barer
CHM | Chairman | 76 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+33,25% | 704 mld. | |
+28,59% | 577 mld. | |
-3,55% | 348 mld. | |
+18,16% | 327 mld. | |
+4,36% | 288 mld. | |
+14,81% | 234 mld. | |
+4,93% | 198 mld. | |
-9,78% | 194 mld. | |
-3,69% | 147 mld. |